KCNQ4 and adenocarcinoma: Notably, KCNQ4 demonstrated favorable prognosis in BRCA (0.37%), ESCA (1.65%), and LUAD (adenocarcinoma) (1.77%) with low mutation frequency, whereas it exhibited poor prognosis in UCEC with high mutation frequency (3.02%).